The European Medicines Agency's CHMP has recommended approval for Alnylam's Onpattro (patisiran), a groundbreaking siRNA therapy for hereditary transthyretin-mediated amyloidosis with polyneuropathy.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.